Scarica l'app Stockscreener
101.99
2.92%
-3.07
Dopo l'orario di chiusura:
103.25
1.26
+1.24%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Incyte Corp Borsa (INCY) Ultime notizie
Why Incyte (INCY) is a Top Value Stock for the Long-Term - Yahoo Finance
Incyte Corporation $INCY Stock Position Raised by Massachusetts Financial Services Co. MA - MarketBeat
Incyte Corporation (NASDAQ:INCY) Nasdaq Top 100 Research Depth - Kalkine Media
Engaging In Insider Activity, Patrick Mayes At Incyte Exercises Options Worth $0 - Benzinga
Thomas Tray Decides To Exercise Options At Incyte Worth $0 - Benzinga
Engaging In Insider Activity, Matteo Trotta At Incyte Exercises Options Worth $0 - Benzinga
Breaking Update: PABLO CAGNONI Engages In Options Exercise At Incyte Realizing $0 - Benzinga
What Investors Should Know Before Buying Incyte Stock (NASDAQ:INCY) - Seeking Alpha
Incyte Corp. Stock Underperforms Wednesday When Compared To Competitors Despite Daily Gains - 富途资讯
Reassessing Incyte (INCY) Valuation After Wells Fargo’s Neutral Downgrade - Yahoo Finance
Wells Fargo & Company Downgrades Incyte (NASDAQ:INCY) to Hold - MarketBeat
Sun Pharma settles litigation with Incyte Corp over hair loss drug Leqselvi - MSN
Incyte (INCY) Faces Downgrade with Revised Price Target by Wells Fargo | INCY Stock News - GuruFocus
IBM To Rally Around 8%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
Wells Fargo downgrades Incyte stock to Equal Weight as upgrade thesis plays out - Investing.com
Incyte (INCY) Faces Downgrade and Adjusted Price Target by Wells Fargo - GuruFocus
New Incyte Drug Combo Shows Power Against Deadly Lymphoma - mychesco.com
EC approves label expansion of INCY's lymphoma drug Minjuvi - MSN
Why Incyte (INCY) Stock Is Trading Up Today - Finviz
Is Incyte (INCY) Still Attractively Priced After Its Strong 1 Year Share Price Gain? - Yahoo Finance
Incyte (INCY) Receives Updated Buy Rating from TD Cowen | INCY S - GuruFocus
Incyte (NASDAQ:INCY) Given New $128.00 Price Target at TD Cowen - MarketBeat
Palmetto Grain Brokerage - Palmetto Grain Brokerage
Earnings Preview: What To Expect From Incyte's Report - Barchart.com
GRIMES & Co WEALTH MANAGEMENT LLC Sells 16,883 Shares of Incyte Corporation $INCY - MarketBeat
Analysts Offer Insights on Healthcare Companies: Incyte (INCY), SI-Bone (SIBN) and Guardant Health (GH) - The Globe and Mail
Lobbying Update: $70,000 of INCYTE CORPORATION lobbying was just disclosed - Quiver Quantitative
Will Incyte (INCY) Beat Estimates Again in Its Next Earnings Report? - Finviz
Incyte Corporation (INCY) Stock Analysis: Strong Revenue Growth and Strategic Developments in the Biotech Sector - DirectorsTalk Interviews
Incyte Corp. stock underperforms Monday when compared to competitors - MSN
ImmunityBio, Xencor Drugs Win E.U. Nods - Los Angeles Business Journal
INCY's phase III Monjuvi study meets key goals in first-line lymphoma - MSN
What margin trends mean for Incyte Corporation stockOil Prices & High Return Trade Guides - Улправда
Incyte Corporation $INCY Stock Holdings Increased by Cerity Partners LLC - MarketBeat
Will Incyte Corporation (ICY) stock beat value stocks2025 Analyst Calls & Smart Investment Allocation Tips - ulpravda.ru
Incyte Corporation Stock Live Price, Chart, Analysis, News & Forecast – Buy, Sell & Trade US Equities Today - livemint.com
Incyte Corporation (INCY) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Incyte jumps amid takeover speculation - MSN
Bull of the Day: Eli Lilly (LLY) - Finviz
Can Incyte Corporation stock reach $100 price targetExit Point & Scalable Portfolio Growth Methods - ulpravda.ru
Why Incyte Corporation (ICY) stock is a strong buy callGap Down & Expert Approved Momentum Ideas - ulpravda.ru
Can Incyte Corporation stock beat market expectations this quarter2025 Macro Impact & Low Volatility Stock Recommendations - ulpravda.ru
Can Incyte Corporation stock hit analyst price targets2025 Key Lessons & Safe Entry Momentum Stock Tips - ulpravda.ru
Incyte (INCY) Is Up 11.9% After Phase 3 frontMIND Success in First-Line High-Risk DLBCL - Yahoo Finance
Incyte Corp. stock underperforms Wednesday when compared to competitors despite daily gains - MarketWatch
Incyte Corp EVP & Chief Medical Officer Sells 15,634 Shares - TradingView — Track All Markets
Incyte (INCY) Stock Is Up, What You Need To Know - Finviz
Incyte (NASDAQ:INCY) Sets New 12-Month High on Analyst Upgrade - MarketBeat
Incyte eyes first-line nod for Tafasitamab in aggressive lymphoma - Indian Pharma Post
Incyte stock hits 52-week high at $109.38 - Investing.com
Incyte Corp. (NASDAQ:INCY) Emerges as a Compelling Value Stock with Strong Fundamentals - Chartmill
INCY: Morgan Stanley Boosts Price Target to $94 in Latest Analys - GuruFocus
Incyte Corp. stock outperforms competitors on strong trading day - MarketWatch
Dow, S&P 500 Hit Record Highs; Guardant, Intuitive Surgical, Incyte In Focus - Investor's Business Daily
Incyte: Maintaining Buy Rating As Hem/Oncology Portfolio Adds 2 Recent Wins (NASDAQ:INCY) - Seeking Alpha
INCY's Phase III Monjuvi Study Meets Key Goals in First-Line Lymphoma - Finviz
Incyte's Monjuvi poised for first-line DLBCL expansion after pivotal study win - FirstWord Pharma
Incyte (NASDAQ:INCY) Price Target Raised to $94.00 - MarketBeat
Incyte reports positive results in late stage trial of lymphoma drug - Delaware Business Now
2.36%
0.99%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):